J3301 HCPCS code: Injection, triamcinolone acetonide, not otherwise specified, 10 mg
J3301 is the HCPCS Level II code for injection, triamcinolone acetonide, not otherwise specified, 10 mg. In 2024 Medicare paid an average of $0.72 per service for J3301 across 18,042,461 services. Its Medicare coverage code is D (Special coverage instructions apply): Medicare covers it when its national or local coverage criteria are met. The NCCI unit limit is 16 per day on outpatient hospital claims. Medicare volume rose 8% from 2022 to 2024 (16,683,786 to 18,042,461 services). In 2024, about 106,517 clinicians billed Medicare for J3301 for 2,222,767 beneficiaries; Florida, California, Texas accounted for 23% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 1991-01-01 |
| Last action effective | 2009-01-01 |
Who bills J3301 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 106,517 |
| Medicare beneficiaries | 2,222,767 |
| States with claims | 57 |
| Share of services in top 3 states (Florida, California, Texas) | 23% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J3301, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 16,683,786 | 2,194,525 | $1.13 | $0.85 |
| 2023 | 17,389,845 | 2,201,890 | $1.06 | $0.80 |
| 2024 | 18,042,461 | 2,222,767 | $0.97 | $0.72 |
States with the most J3301 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 1,675,907 | $0.74 |
| California | 1,303,962 | $0.74 |
| Texas | 1,178,020 | $0.71 |
| Pennsylvania | 966,658 | $0.73 |
| North Carolina | 890,080 | $0.72 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 16 | Prescribing Information |
| practitioner claims | 16 | Prescribing Information |
Medicare policy articles for this code
- A57114: Billing and Coding: Trigger Point Injections (First Coast Service Options, Inc. (MAC - Part B))
- A57751: Billing and Coding: Trigger Point Injections (Novitas Solutions, Inc. (MAC - Part A, MAC - Part B))
Covered diagnoses (2 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| M79.12 | Myalgia of auxiliary muscles, head and neck | 2 |
| M79.18 | Myalgia, other site | 2 |
What changed for J3301
- 1991-01-01: J3301 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J3301?
J3301 is the HCPCS Level II code for injection, triamcinolone acetonide, not otherwise specified, 10 mg. Short descriptor: "Triamcinolone acet inj nos".
How much does Medicare pay for J3301?
In 2024, the average Medicare payment was $0.72 per service (average allowed $0.97).
Does Medicare cover J3301?
Coverage code D — Special coverage instructions apply. Medicare covers it when its national or local coverage criteria are met.
Which diagnoses support coverage for J3301?
Medicare policy articles that cite J3301 list 2 covered ICD-10-CM diagnosis codes across 2 articles. The most cited include M79.12 (Myalgia of auxiliary muscles, head and neck), M79.18 (Myalgia, other site). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J3301 can be billed per day?
16 on outpatient hospital claims; 16 on practitioner claims (NCCI medically unlikely edits).
Related J33 codes
- J3300 — Injection, triamcinolone acetonide, preservative free, 1 mg
- J3302 — Injection, triamcinolone diacetate, per 5 mg
- J3303 — Injection, triamcinolone hexacetonide, per 5 mg
- J3304 — Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
- J3305 — Injection, trimetrexate glucuronate, per 25 mg
- J3310 — Injection, perphenazine, up to 5 mg
- J3315 — Injection, triptorelin pamoate, 3.75 mg
- J3316 — Injection, triptorelin, extended-release, 3.75 mg
- J3320 — Injection, spectinomycin dihydrochloride, up to 2 gm
- J3350 — Injection, urea, up to 40 gm
- J3355 — Injection, urofollitropin, 75 iu
- J3357 — Ustekinumab, for subcutaneous injection, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J3301
- Watch J3301 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J3301
Sources: CMS HCPCS Level II release October 2025; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.